Aurinia Pharmaceuticals (FRA:IKAP) Ending Cash Position : €59.3 Mil (As of Mar. 2024)

View and export this data going back to 2000. Start your Free Trial

What is Aurinia Pharmaceuticals Ending Cash Position?

Aurinia Pharmaceuticals's Ending Cash Position for the quarter that ended in Mar. 2024 was €59.3 Mil.

Aurinia Pharmaceuticals's quarterly Ending Cash Position increased from Sep. 2023 (€43.5 Mil) to Dec. 2023 (€44.8 Mil) and increased from Dec. 2023 (€44.8 Mil) to Mar. 2024 (€59.3 Mil).

Aurinia Pharmaceuticals's annual Ending Cash Position declined from Dec. 2021 (€205.2 Mil) to Dec. 2022 (€88.9 Mil) and declined from Dec. 2022 (€88.9 Mil) to Dec. 2023 (€44.8 Mil).

Aurinia Pharmaceuticals Ending Cash Position Historical Data

The historical data trend for Aurinia Pharmaceuticals's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aurinia Pharmaceuticals Ending Cash Position Chart

Aurinia Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

Get a 7-Day Free Trial

275.42

223.87

205.23

88.90

44.82

Aurinia Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Ending Cash Position	Get a 7-Day Free Trial															83.13	75.42	43.47	44.82	59.30

Aurinia Pharmaceuticals Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Aurinia Pharmaceuticals's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	86.355	+	-41.537
	=	44.8

Aurinia Pharmaceuticals's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	44.965	+	14.337
	=	59.3

Aurinia Pharmaceuticals Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Aurinia Pharmaceuticals's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Aurinia Pharmaceuticals (FRA:IKAP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aurinia Pharmaceuticals Inc (FRA:IKAP) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

AUPH:USA IKAP:Germany

Address

4464 Markham Street, Suite 1203, Victoria, BC, CAN, V8Z 7X8

Website

https://www.auriniapharma.com

Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), and Dry Eye Syndrome (DES). Geographically, it derives maximum revenue from the United States.

Aurinia Pharmaceuticals (FRA:IKAP) Headlines

No Headlines